Anti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company

Alternative Names: CART-19 cells - Beijing Pregene Science and Technology Company; CD19 specific chimeric antigen receptor T-cells - Beijing Pregene Science and Technology Company

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Pregene Science and Technology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Aug 2017 Phase-I/II clinical trials in Acute lymphoblastic leukaemia (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral) (NCT03263208)
  • 01 May 2017 Phase-I/II clinical trials in B-cell lymphoma (In the elderly, Second-line therapy or greater, In adults, Adjunctive treatment, Refractory metastatic disease) in China (IV) (NCT03146533)
  • 01 Sep 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, In adolescents, In adults, In children, In the elderly) in China (Parenteral) (NCT02924753)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top